NCT00628043

Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients

A Phase Ⅲ Randomized Double-Blind Placebo-Controlled Study of Epoetin Beta for the Treatment of Chemotherapy-Induced Anemia (CIA) in Cancer Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Chugai Pharmaceutical · Industry
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to anemic patients with lung cancer or gynecologic cancer undergoing chemotherapy.

Conditions

• Anemia

Interventions

Type	Name	Description
DRUG	epoetin beta	Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
DRUG	placebo	Subcutaneous administration of placebo once-weekly for 12 weeks

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-05-01
• Completion: 2009-09-01
• First posted: 2008-03-04
• Last updated: 2009-09-18

Locations

6 sites across 1 country: Japan